Opti-mal Update For Lung Awaited OptiTROP-Lung06 Readout

Research evidence excerpt

Opti-mal Update For Lung Awaited OptiTROP-Lung06 Readout

Pharmaceuticals (Major) & Large Cap Biotechnology

FLASH

FLASH: MERCK (MRK) July 15, 2026

Opti-mal Update For Lung Awaited OptiTROP-Lung06 Rating:

Readout Outperform

Price:

A second positive phase 3 readout for sac-TMT. Kelun-Biotech (not covered) $120.78

announced this evening that OptiTROP-Lung06, its Chinese-only phase 3 Price Target:

$150trial evaluating sac-TMT plus Merck's (MRK) pembrolizumab, met its primary % Upside:

endpoint of PFS at a prespecified interim analysis, per IDMC review. The trial 24.2%

compared the combination against pembrolizumab plus pemetrexed and platinum-

Source: FactSet, Wolfe Research

based chemotherapy in PD-L1-negative (TPS<1%), non-squamous NSCLC and Priced as of 07/14/26

demonstrated a statistically significant PFS improvement and a positive, yet still

immature, OS trend. Its safety profile was consistent with prior data with no new

signals observed.

Sac-TMT has now shown benefit across the spectrum of PD-L1 patients. Today's

update follows the company's OptiTROP-Lung05's primary endpoint win in PD-L1- Alexandria Hammond

positive NSCLC (our take here from the presentation at ASCO), giving Kelun two ahammond@wolferesearch.com

positive phase 3 readouts spanning the full spectrum of PD-L1 patients. We'd remind (646) 582-9320 View Alexandria’s Research

the core pushback following the Lung05 presentation was that its impressive PFS HR View MRK Model

(0.28 in TPS 1-49%) was a reflection of a weak comparator, pembro monotherapy, View Comp Table

rather than the real world SoC of pembro+chemo. Lung06 resolves this by testing

Cameron DeGuzman

the combination against pembro+chemo itself in the more difficult to treat PD-L1 cdeguzman@wolferesearch.com